Seoul Economic Daily EnglishQwen · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 13:31:01(首尔 14:31)·⟳ 抓取 13:43:46 +12m45s·⚡ 决策 09-14 18:20:38 +4h36m·43.1 天前
韩国柳韩洋行（000100.KS）在 WCLC 2026 上仅披露口服 HER2 靶向抗癌药 YH42946 的 1/2 期试验设计与进度，无任何数据读出
柳韩洋行本次只是在 WCLC 2026 重述一个 2023 年已引进、已在进行中的 1/2 期试验的设计与时间表，没有安全性/疗效数据、没有监管受理或里程碑、没有金额或权益变更；按生物医药『阶段迁移』标准，资产阶段未发生任何变化，相对 5.82 万亿韩元市值不构成可在 1–10 个交易日内定价的增量。当日股价 79,100 韩元跌 0.38%、量比 0.62 倍，市场亦未反应；卖方（含 Morgan Stanley 目标价由 11.3 万下调至 9.7 万韩元、另一家 Underweight/PT 8.5 万）与 20 日 -5.5%、距 52 周高 -38% 的下行轨迹，使任何弱催化的做多都不具正期望，做空红线亦不满足（本事件非公司级利空）。故 AVOID，等待年底前 1 期实际数据读出这一真实催化。
📄 原文Seoul Economic Daily English↗ 原文
Yuhan Speeds Up Development of Oral HER2 Cancer Drug YH42946
Seoul Economic Daily Skip to main content Seoul Economic Daily Seoul Economic Daily KST Seoul Economic Daily Korea's Le…
不做 柳韩洋行 Yuhan Corporation（000100.KS）
无增量事实：WCLC 2026 只披露 YH42946 的 1/2 期试验设计与进度（年内取 1 期结果、2027 年初启动 2 期），没有安全性/疗效数据、没有监管受理或里程碑、没有金额与权益变更，脑转移疗效仍只有动物实验支持，资产阶段未发生任何迁移。量级上，相对 5.82 万亿韩元市值这是一个数年后才可能兑现收入的早期期权；市场当日已给出答案——收 79,100 韩元跌 0.38%、量比 0.62 倍，无异动。执行面，韩国市场此刻已收盘，最近可成交为 9 月 15 日开…
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
会议披露的是 1/2 期试验『设计与进度』而非数据，资产阶段与市场预期均未改变，量级上又远小于 5.82 万亿韩元市值；股价与量能当日零反应，卖方偏空且股价处下行通道，没有可交易的短线 edge，判定不做。
🔎 新鲜度:最早出现 2026-09-14 · 扩散 low · price-in 风险 low ↗
消息传播链
- 带署名记者的成熟财经媒体当日报道柳韩洋行在 WCLC 2026（首尔 COEX）的会议披露；内容明确限定为『试验设计与当前状态』＋年内取 1 期结果、2027 年初启动 2 期的公司计划表述，没有任何数据表格或阳性结果市场反应:000100.KS 当日收 79,100 韩元、跌 0.38%，量比 0.62 倍（低于 20 日均量），日内高低 77,800–80,100，无异动，市场未把该披露当作催化定价
- 2026-09-14其它WCLC 2026 现场（延世癌症中心 林善敏教授报告）／韩文原稿非一手报告主体为学术机构研究者，原始载体是会议报告与 SED 韩文原稿；本轮 Web 检索服务返回大量无关结果，未能取得韩文原稿链接与其它媒体转载情况，故传播广度只能确认为『低到未知』
关键理由
- 本次事件的实质是既有 1/2 期计划的会议重述：无人体数据、无监管推进、无金额或权益变化，脑转移疗效仍停留在动物实验阶段，最早的收入兑现也在数年之后
- 相对 5.82 万亿韩元市值（当日量比仅 0.62 倍、股价 -0.38%），一个 1 期资产的期权价值不足以驱动短线重定价，真正的催化点是年底前 1 期安全性/初步疗效数据读出
主要风险
- 若年底前 1 期数据显示良好安全性并在 HER2 突变或 EGFR 外显子 20 插入（尤其脑转移）人群出现早期疗效信号，则催化强度会质变，需要重新研判而非沿用本次结论
- 本轮 Web 检索返回大量无关结果，未能用韩文原始报道核验会议是否附带未见于英文稿的初步数据，这是本结论的主要不确定性
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-07-30 · 影响 weakens
内部研报显示柳韩洋行被两家机构评为 Underweight：一篇 1Q26 业绩点评 PT 85,000 韩元（lazertinib 放量偏慢、销售组合利润率下降），一篇 2026-06-28 Risk/Reward 更新将 PT 由 113,000 下调至 97,000 韩元；2Q26 点评指公司维持 2026 年国内 lazertinib 销售 1,000 亿韩元、royalty 450 亿韩元目标但上半年仅完成 410 亿/120 亿，目标高度后置
检索:Yuhan Corp 000100 KS pipeline catalyst lazertinib royalty valuation 2026 原文 ↗ - 做多前查反向 · 来源 stock_quote · 日期 2026-09-14 · 影响 weakens
13 周指数化轨迹自 108 回落至 101，20 日累计 -5.5%、距 52 周高 -38.5%，20 日已实现波动率仅 2.45%；事件前 10 日无放量抢跑（量比 0.62 倍），事件日 -0.38%——既无泄露式异动，也无对披露的任何正向反应，属持续偏弱轨迹而非超跌反弹形态
检索:000100.KS 近 20 日逐日走势与量价（事件前异动/趋势形状） 原文 ↗ - 做多前查反向 · 来源 search_case_library · 日期 2026-09-04 · 影响 supports
000100.KS 全历史 13 条相关决策中 ENTER 0 条，近期被刷屏的多为总统奖、研发合作备忘录、补充剂新品等软催化并全部判『不做』；唯一带来实质股价反应的是 2026-07-24 的 4,200 亿韩元注销股份计划（当日 +7%），说明该股短线重定价需要资本/业绩层面的硬增量，而非管线叙事
检索:柳韩洋行近期同类软催化（管线/合作/产品发布）我们如何判、市场如何反应 - 做空前查反向 · 来源 web · 日期 2026-09-14 · 影响 none
本次事件不含任何负面事实：无试验失败、无安全性信号、无监管阻碍、无指引下调，仅为进度与设计披露；卖方偏空与股价下行属存量风险，不构成事件级利空，做空红线的『明确强空催化』不满足
检索:YH42946 / 柳韩洋行本次披露是否含公司级新增利空 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例缺失没有改变结论，只限制了本可以提供的幅度参考；最终以 materiality（5.82 万亿韩元市值 vs 无数据的 1 期资产）＋零价格反应＋下行趋势与卖方偏空（PT 8.5 万/9.7 万韩元，Underweight）共同支撑 AVOID
方向:无可采信先例：本轮四次 Web 检索（韩文与英文、含 YH42946/J INTS BIO/WCLC 组合词）返回的均为与本事件完全无关的结果（彩票、宠物用品、DeepSeek 讨论等），检索服务对本主题实质不可用，未能取得任何带首发链接与时间戳的真实同类事件，因此不提交 event_study，以免编造锚点
涨幅量级:未做幅度校准；本次结论不依赖先例幅度——事件不含数据读出，属『无增量事实』类，幅度校准对做/不做没有影响
形态:无先例可判见光死/高开低走；改用直接市场证据替代：当日 000100.KS 收 -0.38%、量比 0.62 倍，连『见光』都没有出现，说明该披露未被市场当作催化
工具执行结果 · 成功 10 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 26 ms
{"result": "search_processed_events:agent query=`j ints bio her2 egfr exon 20 license | yuhan phase 1/2 oral her2 targeted therapy brain metastases | yuhan yh42946 口服 her2 靶向药 | 유한양행 yh42946 wclc 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或 - fetch_decision_experience 成功 stock_tools HTTP · 89 ms
{ - web_search 成功 Bing RSS · 291 ms
Bing RSS 搜索结果（原始查询:유한양행 YH42946 WCLC 2026 경구용 HER2 표적항암제 임상1상） - web_search 成功 Bing RSS · 292 ms
Bing RSS 搜索结果（原始查询:Yuhan YH42946 J INTS BIO oral HER2 EGFR exon 20 phase 1 data） - stock_quote 降级 stock_tools HTTP · 6,608 ms
{ - search_case_library 成功 stock_tools HTTP · 88 ms
{"result": "search_case_library「000100.KS」—— 与这些标的相关的自家决策案例(本页 12 条,该标的全历史相关记录共 13 条；ENTER 只按该标的自己的腿统计):\n◆ 000100.KS：相关历史决策 13 条 · 其中该标的 ENTER 0 条(0.0%) · 我们从没在这只票上 ENTER 过\n【对所查标的真 ENTER 过的:0 条 —— 相关案例里没有该标的自己的 ENTER 腿】\n【最近 12 条其它决策(多为「不做」,用来看这票最近在被什么消息刷屏)】\n• 2026-09-04 UTC 不做 · 事件:韩国药企Yuhan因资源循 - kb_search 成功 stock_tools HTTP · 2,334 ms
{ - web_search 成功 Bing RSS · 458 ms
Bing RSS 搜索结果（原始查询:"YH42946" Yuhan oral HER2 targeted therapy WCLC Seoul Phase 1） - web_search 成功 Bing RSS · 250 ms
Bing RSS 搜索结果（原始查询:유한양행 경구용 HER2 표적 항암제 YH42946 세계폐암학회 임상） - web_search 成功 Bing RSS · 253 ms
Bing RSS 搜索结果（原始查询:Yuhan Corporation oral HER2 cancer drug YH42946 World Conference on Lung Cancer 2026） - kb_search 成功 stock_tools HTTP · 4,084 ms
{
原文全文
展开原文 · 4,592 字
Yuhan Speeds Up Development of Oral HER2 Cancer Drug YH42946 - Seoul Economic Daily
Skip to main content
Seoul Economic Daily
Seoul Economic Daily
KST
Seoul Economic Daily
Korea's Leading Business News Since 1960
한국어
Menu
Saved Articles
Newsletters
AI KEY
Settings
|
Summary
|
Save
A
A
A
Lim Sun-min, professor of medical oncology at Yonsei Cancer Center, presents Phase 1/2 trial results for Yuhan's oral HER2-targeted therapy "YH42946" at the 2026 World Conference on Lung Cancer (WCLC) held at COEX in Seoul. Photo courtesy of Yuhan Corp.
Yuhan Corporation is accelerating clinical development of YH42946, an oral HER2-targeting cancer drug, aiming to secure early Phase 1 results by the end of this year and begin a Phase 2 trial early next year.
The company said on the 14th that it disclosed the design and current status of the Phase 1/2 trial of YH42946 at the 2026 World Conference on Lung Cancer (WCLC) held at COEX in Seoul.
YH42946 is an oral targeted therapy aimed at HER2, a protein that drives cancer cell growth. Yuhan has been developing the drug since licensing the technology from J INTS BIO in 2023. Its target patient population covers not only HER2 mutations, amplification and overexpression but also cancers carrying EGFR exon 20 insertion mutations.
The drug's potential against brain metastases is drawing particular attention. Patients with HER2 or EGFR exon 20 mutations frequently develop brain metastases, but some existing treatments require intravenous administration or carry limitations such as toxicity. YH42946 is being developed as an oral drug, and animal studies confirmed its effect on tumors that had spread to the brain.
The ongoing Phase 1/2 trial enrolls patients with advanced or metastatic solid tumors carrying HER2 or EGFR exon 20 mutations. The Phase 1 portion escalates doses in stages to assess safety, the appropriate dose and early anti-tumor activity.
Yuhan expects to obtain Phase 1 results on safety and early anti-tumor activity by the end of this year. Based on those findings, the company plans to select two dose levels and begin a Phase 2 trial in early 2027 to determine the optimal dose. It then intends to expand development to other types of solid tumors with HER2 abnormalities.
"YH42946 is a new treatment option for patients with solid tumors carrying HER2 abnormalities and EGFR exon 20 insertion mutations — an oral drug that can also be expected to show effect on brain metastatic lesions," said Kim Yeul-hong, president and head of R&D at Yuhan. "We will move quickly to establish the recommended dose and advance follow-up development."
#
Yuhan
#
YH42946
#
HER2
#
LungCancer
#
WCLC2026
#
TargetedTherapy
#
KoreaPharma
Original reporting by
Park Hong-yong
for Seoul Economic Daily.
AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.
Translated by AI on
Sep 14, 2026
View Korean original
↗
Translation Policy
Watch · Seoul Economic Daily
More →
2:20
KB Securities Sees Samsung Back at No.1, SK Hynix at No.3 Next Year | September 14 2026 | Securities Daily
2:20
Most Read This Week
1
-
5
‹
›
1
JBL Launches Xtreme 5 Bluetooth Speaker With Stronger Bass
2
Hyundai, POSCO Break Ground on $5.8 Billion U.S. Steel Mill
3
China Pumps 300 Billion Yuan Into Eight Financial Firms
4
Korea to Offer 20,000 Homes at 1,000 Won a Day for Young Adults
5
Samsung, SK hynix Memory Stockpiles Fall Below 10 Days
← Back to Home
AI KEY
Preview
↗
Korean Corporate Intelligence Hub
KOSPI · KOSDAQ · 12 sectors
A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.
Click to explore AI KEY
→
Open AI KEY in full screen
↗
Korea Company Atlas
Preview
↗
Market Ontology · The Feedback Loop
KFTC 2025 · 92 groups · 121,954 articles
An English ontology of the Korean market — how companies, the media, the government and the National Assembly move each other in a loop. Korea's named controlling persons and designated business groups are a mechanism, not a risk to be priced blind.
Click to explore the atlas
→
Open Atlas in full screen
↗
SIGNAL
Now live
↗
English Edition · Capital Markets
M&A · IPO · PE · Fund Flows
SIGNAL English Edition is live — Korea's deal desk reporting in English. M&A, IPOs, private equity and fund flows, covered daily for global institutional investors. Browse free; subscriber-only scoops at the 50% intro rate.
Click to explore SIGNAL
→
Open SIGNAL in full screen
↗
Skip to main content
Seoul Economic Daily
Seoul Economic Daily
KST
Seoul Economic Daily
Korea's Leading Business News Since 1960
한국어
Menu
Saved Articles
Newsletters
AI KEY
Settings
|
Summary
|
Save
A
A
A
Lim Sun-min, professor of medical oncology at Yonsei Cancer Center, presents Phase 1/2 trial results for Yuhan's oral HER2-targeted therapy "YH42946" at the 2026 World Conference on Lung Cancer (WCLC) held at COEX in Seoul. Photo courtesy of Yuhan Corp.
Yuhan Corporation is accelerating clinical development of YH42946, an oral HER2-targeting cancer drug, aiming to secure early Phase 1 results by the end of this year and begin a Phase 2 trial early next year.
The company said on the 14th that it disclosed the design and current status of the Phase 1/2 trial of YH42946 at the 2026 World Conference on Lung Cancer (WCLC) held at COEX in Seoul.
YH42946 is an oral targeted therapy aimed at HER2, a protein that drives cancer cell growth. Yuhan has been developing the drug since licensing the technology from J INTS BIO in 2023. Its target patient population covers not only HER2 mutations, amplification and overexpression but also cancers carrying EGFR exon 20 insertion mutations.
The drug's potential against brain metastases is drawing particular attention. Patients with HER2 or EGFR exon 20 mutations frequently develop brain metastases, but some existing treatments require intravenous administration or carry limitations such as toxicity. YH42946 is being developed as an oral drug, and animal studies confirmed its effect on tumors that had spread to the brain.
The ongoing Phase 1/2 trial enrolls patients with advanced or metastatic solid tumors carrying HER2 or EGFR exon 20 mutations. The Phase 1 portion escalates doses in stages to assess safety, the appropriate dose and early anti-tumor activity.
Yuhan expects to obtain Phase 1 results on safety and early anti-tumor activity by the end of this year. Based on those findings, the company plans to select two dose levels and begin a Phase 2 trial in early 2027 to determine the optimal dose. It then intends to expand development to other types of solid tumors with HER2 abnormalities.
"YH42946 is a new treatment option for patients with solid tumors carrying HER2 abnormalities and EGFR exon 20 insertion mutations — an oral drug that can also be expected to show effect on brain metastatic lesions," said Kim Yeul-hong, president and head of R&D at Yuhan. "We will move quickly to establish the recommended dose and advance follow-up development."
#
Yuhan
#
YH42946
#
HER2
#
LungCancer
#
WCLC2026
#
TargetedTherapy
#
KoreaPharma
Original reporting by
Park Hong-yong
for Seoul Economic Daily.
AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.
Translated by AI on
Sep 14, 2026
View Korean original
↗
Translation Policy
Watch · Seoul Economic Daily
More →
2:20
KB Securities Sees Samsung Back at No.1, SK Hynix at No.3 Next Year | September 14 2026 | Securities Daily
2:20
Most Read This Week
1
-
5
‹
›
1
JBL Launches Xtreme 5 Bluetooth Speaker With Stronger Bass
2
Hyundai, POSCO Break Ground on $5.8 Billion U.S. Steel Mill
3
China Pumps 300 Billion Yuan Into Eight Financial Firms
4
Korea to Offer 20,000 Homes at 1,000 Won a Day for Young Adults
5
Samsung, SK hynix Memory Stockpiles Fall Below 10 Days
← Back to Home
AI KEY
Preview
↗
Korean Corporate Intelligence Hub
KOSPI · KOSDAQ · 12 sectors
A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.
Click to explore AI KEY
→
Open AI KEY in full screen
↗
Korea Company Atlas
Preview
↗
Market Ontology · The Feedback Loop
KFTC 2025 · 92 groups · 121,954 articles
An English ontology of the Korean market — how companies, the media, the government and the National Assembly move each other in a loop. Korea's named controlling persons and designated business groups are a mechanism, not a risk to be priced blind.
Click to explore the atlas
→
Open Atlas in full screen
↗
SIGNAL
Now live
↗
English Edition · Capital Markets
M&A · IPO · PE · Fund Flows
SIGNAL English Edition is live — Korea's deal desk reporting in English. M&A, IPOs, private equity and fund flows, covered daily for global institutional investors. Browse free; subscriber-only scoops at the 50% intro rate.
Click to explore SIGNAL
→
Open SIGNAL in full screen
↗
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。